Differentiating early-stage nasopharyngeal carcinoma from adenoidal hypertrophy via SLC40A1 expression and developing a prognostic model for disease progression.

IF 2.9 3区医学 Q2 ONCOLOGY

American journal of cancer research Pub Date : 2025-08-15 eCollection Date: 2025-01-01 DOI:10.62347/ZBIH5385

Hongwei Wang, Suqing Qi, Chaobing Liu, Zhenhua Qiao, Chao Zhang

{"title":"Differentiating early-stage nasopharyngeal carcinoma from adenoidal hypertrophy via SLC40A1 expression and developing a prognostic model for disease progression.","authors":"Hongwei Wang, Suqing Qi, Chaobing Liu, Zhenhua Qiao, Chao Zhang","doi":"10.62347/ZBIH5385","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the expression and diagnostic utility of solute carrier family 40 member 1 (SLC40A1) in differentiating early diagnosis of nasopharyngeal carcinoma (NPC) from adenoid hypertrophy (AH), and to develop a prognostic prediction model based on its expression.Methods: Public databases were used to analyze SLC40A1 expression in head and neck squamous cell carcinoma (HNSC) and its association with prognosis, pathological staging, and immune infiltration. A total of 102 NPC patients, 97 AH patients, and 101 healthy controls were enrolled between October 2021 and October 2023. SLC40A1 expressions in tissues and serum were assessed via real-time reverse transcription polymerase chain reaction and Western blotting. Associations with clinicopathological features were evaluated. Receiver operating characteristic (ROC) curves evaluated diagnostic performance. Logistic regression identified prognostic factors, and a predictive model was constructed.Results: Bioinformatics analysis indicated downregulated SLC40A1 in HNSC, negatively associated with tumor (T) stage and distant metastasis (M) stage. Clinical validation showed significantly lower SLC40A1 mRNA and protein levels in NPC compared to AH and controls, with negative correlation to Epstein-Barr virus (EBV) infection (all P<0.05). Serum SLC40A1 mRNA demonstrated 90.20% sensitivity and 62.38% specificity for NPC diagnosis. When combined with EBV DNA, it yielded an improved diagnostic performance (AUC=0.913). Tumor diameter >5 cm and lymph nodes ≥2 were independent risk factors for NPC progression, while high SLC40A1 expression was protective (OR=0.140, 95% CI: 0.028-0.700). The final model achieved 91.67% sensitivity and 72.00% specificity (AUC=0.863).Conclusion: SLC40A1 is significantly downregulated in NPC and may serve as a diagnostic and prognostic biomarker, especially when combined with EBV status.","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 8","pages":"3434-3448"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432563/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/ZBIH5385","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the expression and diagnostic utility of solute carrier family 40 member 1 (SLC40A1) in differentiating early diagnosis of nasopharyngeal carcinoma (NPC) from adenoid hypertrophy (AH), and to develop a prognostic prediction model based on its expression.

Methods: Public databases were used to analyze SLC40A1 expression in head and neck squamous cell carcinoma (HNSC) and its association with prognosis, pathological staging, and immune infiltration. A total of 102 NPC patients, 97 AH patients, and 101 healthy controls were enrolled between October 2021 and October 2023. SLC40A1 expressions in tissues and serum were assessed via real-time reverse transcription polymerase chain reaction and Western blotting. Associations with clinicopathological features were evaluated. Receiver operating characteristic (ROC) curves evaluated diagnostic performance. Logistic regression identified prognostic factors, and a predictive model was constructed.

Results: Bioinformatics analysis indicated downregulated SLC40A1 in HNSC, negatively associated with tumor (T) stage and distant metastasis (M) stage. Clinical validation showed significantly lower SLC40A1 mRNA and protein levels in NPC compared to AH and controls, with negative correlation to Epstein-Barr virus (EBV) infection (all P<0.05). Serum SLC40A1 mRNA demonstrated 90.20% sensitivity and 62.38% specificity for NPC diagnosis. When combined with EBV DNA, it yielded an improved diagnostic performance (AUC=0.913). Tumor diameter >5 cm and lymph nodes ≥2 were independent risk factors for NPC progression, while high SLC40A1 expression was protective (OR=0.140, 95% CI: 0.028-0.700). The final model achieved 91.67% sensitivity and 72.00% specificity (AUC=0.863).

Conclusion: SLC40A1 is significantly downregulated in NPC and may serve as a diagnostic and prognostic biomarker, especially when combined with EBV status.

查看原文本刊更多论文

通过SLC40A1表达鉴别早期鼻咽癌和腺样体肥大并建立疾病进展的预后模型

目的：探讨溶质载体家族40成员1 （SLC40A1）在鼻咽癌（NPC）与腺样体肥大（AH）早期诊断中的表达及诊断价值，并建立基于其表达的预后预测模型。方法：利用公共数据库分析SLC40A1在头颈部鳞状细胞癌（HNSC）中的表达及其与预后、病理分期、免疫浸润的关系。在2021年10月至2023年10月期间，共有102名NPC患者、97名AH患者和101名健康对照者入组。通过实时逆转录聚合酶链反应和Western blotting检测组织和血清中SLC40A1的表达。评估与临床病理特征的关系。受试者工作特征（ROC）曲线评估诊断效果。Logistic回归识别预后因素，构建预测模型。结果：生物信息学分析显示，SLC40A1在HNSC中表达下调，与肿瘤(T)分期和远处转移(M)分期呈负相关。临床验证显示，与AH和对照组相比，鼻咽癌SLC40A1 mRNA和蛋白水平显著降低，且与eb病毒感染呈负相关(所有P5 cm和淋巴结≥2是鼻咽癌进展的独立危险因素，而SLC40A1高表达具有保护作用（OR=0.140, 95% CI: 0.028-0.700）。最终模型的灵敏度为91.67%，特异性为72.00% （AUC=0.863）。结论：SLC40A1在鼻咽癌中显著下调，可能作为诊断和预后的生物标志物，特别是当与EBV状态结合时。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.